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Synthesis of complexes: 
•  aqueous solutions of ZnCl2 and sodium diethyldithiocarbamate (NaEt2DTC) or sodium 
dibenzyldithiocarbamate (NaBz2DTC) were mixed at rate 1:2
•  hard soluble powders immediately originated, which were carefully washed by distilled water 
until negative chloride test and dried by room temperature for several days to constant weight
X-ray analysis and mass spectroscopy:
•  molecular structures of obtained compounds are in conformity with literature (Bonamico et 
al. Acta Crystallogr 1965; Decken et al. Appl Organomet Chem 2006) and are stable in 
aqueous milieu (according to APCI mass spectrometry)
•  Zn(II) in both [Zn(Et2DTC)2] and [Zn(Bz2DTC)2] is chelated by 4 sulfurs with various 
coordination geometry: tetragonal planar (former) and tetrahedral (latter)
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HeLa cells were treated in serum free medium for 30 min with:
b) tumor necrosis factor (TNF), NF-kB-activating cytokine, and [Zn(Bz2DTC)2], b) [Zn(Et2DTC)2]
nuclear translocation of p65 was determined by western bloting
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„ Progress isn’ t based on knowledge, 
it is based on ideas.“  
Sir J. W. Black (Nobel Prize 1988)
At the start of the story: pyrrolidine dithiocarbamate blocks proteolysis of I-kB and hence 
canonical NF- B pathway both κ in vitro (Henkel et al. Nature 1993) and in vivo (Liu et al. Mol 
Pharmacol 1999). Why? These two ideas result from key studies: 1) the I-kB can be stabilized 
through proteasome inhibition or 2) via a blockage of ubiquitination.
At the start of the story: dithiocarbamates are well known activators of AP-1 and AP-1-
dependent gene induction both in vitro and in vivo (Meyer et al. EMBO J 1993; Borrello et al. 
Arch Biochem Biophys 1997 & Biochem Biophys Res Commun 1996). This capability can be 
linked to proteasome inhibition and proteasome-independent NF-kB pathway.
Proteasome inhibitors: dithiocarbamate complexes, formed by reaction with Zn(II) and Cu(II) in 
medium, can enter the cell and inhibit proteasome (Kim et al. Exp Cell 
Res 2004; Chen et al. Cancer Res 2006). They inhibit its chymotrypsin-
like activity (Milacic et al. Cancer Res 2006) as well as bortezomib, 
potent anticancer drug (Adams Cancer Cell 2004). Zn(II) + dimer of
diethyldithiocarbamate (disulfiram) were successfully used for
clinical remission in patient with metastatic ocular melanoma
(Brar et al. Mol Cancer Ther 2004). What is a likely mechanism
of proteasome inhibition by dithiocarbamate complexes?
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SCF inhibitors: pyrrolidine dithiocarbamate inhibits I-kB ubiquitin ligase in cell-free system 
(Hayakawa et al. EMBO J 2003). This ligase belongs to Skp-1/Cul/F box (SCF) family and
is regulated by „ deneddylation“  of Cul1 subunit. Such event requires the isopeptidase activity 
of CSN5 subunit of the COP9 signalosome (Cope et al. BMC Biochem 2006; cf. Schweitzer et 
al. EMBO J 2007). CSN5 contains JAMM motif, sensitive to metals as well as metal chelators 
(Cope et al. Science 2002). See also Cvek & Dvorak Curr Pharm Des 2007 in press
The lid subunit POH1 (Rpn11 in yeast) is responsible for substrate
deubiquitination during proteasomal degradation (Yao et al. Nature 2002).
This protein contains highly conserved Jab1/MPN domain-associated metal-isopeptidase
(JAMM) motif, which is sensitive to metal chelators (Verma et al. Science 2002).
Future directions: most recently, Milennium Pharmaceuticals researchers have reported JAMM 
motif of POH1 as therapeutic drug target for cancer (Gallery et al. Mol Cancer Ther 2007), so 
there are following challenges:
•  extract the general principles of proteasome or CSN5 inhibition from recent studies
•  design of new proteasome or CSN5 inhibitors for cancer therapy (the collaboration with B. A. 
Karmanos Cancer Institute Detriot USA and Department of Chemistry MU Brno)
•  molecular structure of JAMM motif is known (Ambroggio et al. PLoS Biology 2004) and 
hence we can model (in silico) its inhibitors (collaboration wanted)
Future directions: current anticancer research is focused on NF-kB, AP-1 (Mariani et al. Cancer 
Cell 2007), and IKK (Luo et al. Nature 2007), so we need
•  to extract the general principles of NF-kB activation, signaling, and cross-talk with AP-1 from 
recent studies 
•  to answer these questions: what type of coordination sphere and why does trigger NF-kB and 
AP-1 pathways? what implications are there for anticancer therapy?
•  to know in what form and how do dithiocarbamate coordination compounds enter the cell 
(collaboration wanted)
Proteasome-independent „ pathway X“ : phosphorylated p65 (on 
serine 536) is not associated with I-kB and p50, hence its 
activation is totally proteasome-independent (Sasaki et al. J Biol 
Chem 2005). This defines new NF-kB pathway.
Proteasome inhibitors can activate NF-kB & AP-1: bortezomib and MG132, widely used
Zn(II) activates „ pathway X“ : 1. zinc(II) induces AP-1 through MAP kinases (Kim et al. Am J 
Physiol Lung Cell Mol Physiol 2006). 2. zinc(II) exposure causes p65 phosphorylation on 
serine 536 and therefore proteasome-independent NF-kB activation (Kim et al. Cell Signal 
2007).
Indeed, signaling to NF-κB can be MEKK3-mediated: this pathway 
involves IKK3 phosphorylation and IKK1 activation, resulting in p65 
phosphorylation and subsequent I-kB release from NF-kB without I-kB 
(proteasomal) degradation (Yao et al. J Biol Chem 2007).
Moreover, MEKK-3 is (through mitogen activated, = MAP, kinases) involved also in AP-1 
activation (Xu et al. J Biol Chem 2004; Lee et al. Mol Cell Biol 2003). 
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proteasome inhibitors, trigger IKK1/2 mediated p65 phosphorylation (at serine
536) and activation simultaneously with I-kB degradation (Dolcet et al. J
Biol Chem 2006). They, as well as pyrrolidine dithiocarbamate (by 
AP-1 activation: Hartsfield et al. FASEB J 1998), up-regulate heme 
oxygenase-1 gene. This effect of various proteasome inhibitors is NF-
kB inhibition-independent and is mediated by p38/AP-1 pathway (Wu 
et al. Biochem J 2004).
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